Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Venus Medtech Hangzhou Inc
2500Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, and VenusA-Pro; and VenusP-Valve is a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People's Republic of China. Address: No. 88, Jiangling Road, Hangzhou, China, 310051
Analytics
Preço Alvo de Wall Street
66.92 HKDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 2500
Análise de Dividendos 2500
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos 2500
Avaliação de ações 2500
Relatório 2500
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |